Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 293

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 293
---
 Other Jurisdictions - Hong Kong Taxation.”

Hong Kong

Our company and certain of its subsidiaries are subject to Hong Kong Profits Tax laws and regulations. Hong Kong has a two-tiered Profits Tax rates regime under which the first HK$2.0 million ($0.3 million) of assessable profits of qualifying corporations will be taxed at 8.25%, with the remaining assessable profits taxed at 16.5%. Hong Kong Profits Tax has been provided for at the relevant rates on the estimated assessable profits less estimated available tax losses, if any, of these entities as applicable.

Period-to-Period Comparison of Results of Operations

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Revenue

Our revenue was $630.2 million for the year ended December 31, 2024, with the largest component being Oncology/Immunology revenue of $363.4 million, which includes Takeda collaboration revenue of $67.0 million (including $48.1 million upfront & regulatory milestones). This compares to $838.0 million for the year ended December 31, 2023, with the largest component being Oncology/Immunology revenue of $528.6 million, which includes Takeda collaboration revenue of $345.9 million (including $312.0 million upfront & regulatory milestones).

Revenue from oncology products within Oncology/Immunology increased by 65.4% to $271.5 million for the year ended December 31, 2024 compared to $164.2 million for the year ended December 31, 2023, primarily due to:

  An increase in sales of Fruzaqla to $110.8 million for the year ended December 31, 2024 (of which $39.4 million was royalty revenue attributable from in-market sales of $290.6 million, $51.4 mi...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  An increase in sales of Elunate (primarily to Eli Lilly) to $86.3 million for the year ended December 31, 2024 (of which $52.5 million was promotion and marketing services, $15.8 million was sa...  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────